Will new dopamine receptors offer a key to schizophrenia?
Taubes
G
G
D017371:8-Hydroxy-2-(di-n-propylamino)tetralin / Q000031:analogs & derivatives / Q000378:metabolism / Q000627:therapeutic use; D001921:Brain / Q000378:metabolism*; D003024:Clozapine / Q000378:metabolism / Q000627:therapeutic use; D018492:Dopamine Antagonists; D006801:Humans; D011954:Receptors, Dopamine / Q000378:metabolism*; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D050638:Receptors, Dopamine D4; D012559:Schizophrenia / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism
C493593:DRD3 protein, human; C493599:DRD4 protein, human; D018492:Dopamine Antagonists; D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D050638:Receptors, Dopamine D4; D017371:8-Hydroxy-2-(di-n-propylamino)tetralin; C045971:UH 232; D003024:Clozapine